Regeneron Pharmaceuticals, a prominent name in the biotech industry, has had a turbulent ride recently. The company faced a notable setback with its
COPD drug, developed alongside Sanofi, failing a key test and leading to an 18% drop in their share price: a spike in interest from various financial entities was witnessed regardless. Banks and investment firms, such as Toronto Dominion, 111 Capital, GuoLine Advisory Pte Ltd, and First Hawaiian Bank, among others, have either raised their stakes or acquired new shares in REGN. However, investor confidence was rocked with Wells Fargo downgrading Regeneron stock and a reduction in stock rating by RBC Capital. Sanofi and Regeneron experienced mixed results in late-stage COPD Studies, and Regeneron’s stock experienced a 52-week low following these events. On a brighter note, REGN also reported that their drug, Libtayo, showed a 68% reduction in the Risks of Disease Recurrence or Death. Their plans to acquire 23andMe and the adoption of Telesis Bio's gene synthesis platform indicate a strong focus on streamlining R&D and potentially driving future innovation. Despite these setbacks, Jim Cramer hailed Regeneron as one of the most innovative businesses witnessed in two decades.
Regeneron Pharmaceuticals REGN News Analytics from Mon, 10 Mar 2025 07:00:00 GMT to Sat, 31 May 2025 18:12:50 GMT -
Rating -5
- Innovation 8
- Information 6
- Rumor -3
